ATE356200T1 - Kcnq kaliumkanäle und verfahren zur deren modulierung - Google Patents
Kcnq kaliumkanäle und verfahren zur deren modulierungInfo
- Publication number
- ATE356200T1 ATE356200T1 AT98932877T AT98932877T ATE356200T1 AT E356200 T1 ATE356200 T1 AT E356200T1 AT 98932877 T AT98932877 T AT 98932877T AT 98932877 T AT98932877 T AT 98932877T AT E356200 T1 ATE356200 T1 AT E356200T1
- Authority
- AT
- Austria
- Prior art keywords
- kcnq2
- proteins
- kcnq3
- potassium channels
- disease
- Prior art date
Links
- 102000012359 KCNQ Potassium Channels Human genes 0.000 title 1
- 108010022282 KCNQ Potassium Channels Proteins 0.000 title 1
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 abstract 3
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 abstract 3
- 102000015686 KCNQ3 Potassium Channel Human genes 0.000 abstract 2
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010003591 Ataxia Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 101000994667 Homo sapiens Potassium voltage-gated channel subfamily KQT member 2 Proteins 0.000 abstract 1
- 101000994663 Homo sapiens Potassium voltage-gated channel subfamily KQT member 3 Proteins 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 206010028632 Myokymia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 101100397814 Rattus norvegicus Kcnq2 gene Proteins 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 208000032257 benign familial neonatal 1 seizures Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 102000053004 human KCNQ2 Human genes 0.000 abstract 1
- 102000053006 human KCNQ3 Human genes 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5559997P | 1997-08-12 | 1997-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE356200T1 true ATE356200T1 (de) | 2007-03-15 |
Family
ID=21998937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98932877T ATE356200T1 (de) | 1997-08-12 | 1998-06-26 | Kcnq kaliumkanäle und verfahren zur deren modulierung |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US6403360B1 (de) |
| EP (1) | EP1007638B1 (de) |
| JP (1) | JP2001512673A (de) |
| AT (1) | ATE356200T1 (de) |
| AU (1) | AU731087B2 (de) |
| CA (1) | CA2300985A1 (de) |
| DE (1) | DE69837267T2 (de) |
| DK (1) | DK1007638T3 (de) |
| ES (1) | ES2281129T3 (de) |
| WO (1) | WO1999007832A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE356200T1 (de) * | 1997-08-12 | 2007-03-15 | Bristol Myers Squibb Co | Kcnq kaliumkanäle und verfahren zur deren modulierung |
| CA2307316C (en) | 1997-10-24 | 2010-12-21 | University Of Utah Research Foundation | Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies |
| DE60031967D1 (de) * | 1999-04-14 | 2007-01-04 | Merck & Co Inc | Neuartige menschliche kalium-potentialabhängige kanäle |
| WO2000077035A2 (en) * | 1999-06-11 | 2000-12-21 | Neurosearch A/S | Novel potassium channels and genes encoding these potassium channels |
| US6649371B1 (en) | 1999-06-11 | 2003-11-18 | Neurosearch A/S | Potassium channel KCNQ5 and sequences encoding the same |
| US6472165B1 (en) | 1999-08-03 | 2002-10-29 | Arzneimittelwerk Dresden Gmbh | Modulatory binding site in potassium channels for screening and finding new active ingredients |
| BR0012934A (pt) | 1999-08-04 | 2003-07-29 | Icagen Inc | Processos para a redução de dor e de ansiedade |
| US7049137B2 (en) * | 2000-03-21 | 2006-05-23 | Icagen, Inc. | KCNQ5, a novel potassium channel |
| DE10013732A1 (de) * | 2000-03-21 | 2001-09-27 | Aventis Pharma Gmbh | Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems |
| US6617131B2 (en) | 2000-03-21 | 2003-09-09 | Aventis Pharma Deutschland Gmbh | Nucleic acid molecule encoding the potassium channel protein, KCNQ5 |
| AU2001251283A1 (en) * | 2000-04-03 | 2001-10-15 | Lexicon Genetics Incorporated | Human ion channel protein and polynucleotides encoding the same |
| CA2410489A1 (en) * | 2000-05-26 | 2001-12-06 | Bristol-Myers Squibb Company | Human kcnq5 potassium channel, methods and compositions thereof |
| US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
| IL157313A0 (en) | 2001-02-20 | 2004-02-19 | Bristol Myers Squibb Co | Modulators of kcnq potassium channels and uses thereof |
| JP6073230B2 (ja) * | 2010-09-28 | 2017-02-01 | ノノ インコーポレイテッド | Nd2ペプチドおよび神経疾患の治療方法 |
| FR3029113A1 (fr) | 2014-12-02 | 2016-06-03 | Univ Paris-Sud | Composes pour le traitement des maladies mitochondriales |
| US20230124616A1 (en) * | 2020-03-06 | 2023-04-20 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating kcnq2 |
| US20260049061A1 (en) * | 2024-03-18 | 2026-02-19 | HUMANWELL PHARMACEUTICAL US, Inc. | Small molecules as kcnq2/3 (kv7.2/3) channel activators and their medical use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09191882A (ja) * | 1996-01-16 | 1997-07-29 | Japan Tobacco Inc | ヒト新規k+チャネル蛋白質をコードするdnaおよびその断片 |
| ATE356200T1 (de) * | 1997-08-12 | 2007-03-15 | Bristol Myers Squibb Co | Kcnq kaliumkanäle und verfahren zur deren modulierung |
| CA2307316C (en) * | 1997-10-24 | 2010-12-21 | University Of Utah Research Foundation | Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies |
-
1998
- 1998-06-26 AT AT98932877T patent/ATE356200T1/de active
- 1998-06-26 US US09/105,058 patent/US6403360B1/en not_active Expired - Lifetime
- 1998-06-26 DE DE69837267T patent/DE69837267T2/de not_active Revoked
- 1998-06-26 AU AU82665/98A patent/AU731087B2/en not_active Ceased
- 1998-06-26 ES ES98932877T patent/ES2281129T3/es not_active Expired - Lifetime
- 1998-06-26 WO PCT/US1998/013276 patent/WO1999007832A1/en not_active Ceased
- 1998-06-26 DK DK98932877T patent/DK1007638T3/da active
- 1998-06-26 EP EP98932877A patent/EP1007638B1/de not_active Revoked
- 1998-06-26 JP JP2000506317A patent/JP2001512673A/ja active Pending
- 1998-06-26 CA CA002300985A patent/CA2300985A1/en not_active Abandoned
-
2002
- 2002-04-24 US US10/128,870 patent/US7041496B2/en not_active Expired - Lifetime
- 2002-04-24 US US10/131,685 patent/US7262289B2/en not_active Expired - Fee Related
-
2007
- 2007-02-16 US US11/707,363 patent/US7482431B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6403360B1 (en) | 2002-06-11 |
| US7041496B2 (en) | 2006-05-09 |
| DE69837267D1 (de) | 2007-04-19 |
| CA2300985A1 (en) | 1999-02-18 |
| ES2281129T3 (es) | 2007-09-16 |
| AU8266598A (en) | 1999-03-01 |
| EP1007638A1 (de) | 2000-06-14 |
| DE69837267T2 (de) | 2007-10-31 |
| EP1007638A4 (de) | 2004-12-29 |
| AU731087B2 (en) | 2001-03-22 |
| US7482431B2 (en) | 2009-01-27 |
| DK1007638T3 (da) | 2007-05-21 |
| US7262289B2 (en) | 2007-08-28 |
| EP1007638B1 (de) | 2007-03-07 |
| JP2001512673A (ja) | 2001-08-28 |
| US20020168724A1 (en) | 2002-11-14 |
| US20070148692A1 (en) | 2007-06-28 |
| WO1999007832A1 (en) | 1999-02-18 |
| US20030044912A1 (en) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE356200T1 (de) | Kcnq kaliumkanäle und verfahren zur deren modulierung | |
| ATE466883T1 (de) | Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten | |
| DE59807213D1 (de) | 11beta-halogen-7alpha-substituierte-estratriene, verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha-substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln | |
| MXPA02001911A (es) | Anticuerpos ctla-4 humanos y sus usos. | |
| DE69637256D1 (de) | Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle | |
| DE59603216D1 (de) | Esterquats und ihre Verwendung zur Herstellung von oberflächenaktiven Mitteln, insbesondere zur Haar- und Körperpflege | |
| ATE397868T1 (de) | Verfahren zur verbesserung der haut und des pelzes von haustieren | |
| EA200200293A1 (ru) | Бициклические аминокислоты в качестве фармацевтических агентов | |
| DE69839801D1 (de) | Intraokularlinsen und verfahren zur herstellung von eingesgossenen intraokularlinsen | |
| WO2004058704A3 (en) | Quinazolinones as potassium channel modulators | |
| DE69626539D1 (de) | topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen | |
| ATE552891T1 (de) | Kombination von sauren-proteaseenzymen und sauren pufferlösungen sowie deren verwendung | |
| EP1427377A4 (de) | Verfahren und zusammensetzungen zur behandlung oder prävention von hauterkrankungen unter verwendung von bindemitteln, die für das prostataspezifische membranantigen spezifisch sind | |
| EP1409509A4 (de) | Antisense-modulation der expression von c-reactive-protein | |
| ATE299179T1 (de) | Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung | |
| ATE259652T1 (de) | Neuronale verwendungen des bmp-11 | |
| MX209576B (es) | Proceso para la hidrogenacion continua de adiponitrilo | |
| ATE391779T1 (de) | Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal | |
| BR9607745A (pt) | Processo para produzir ácido 5-inosínico ou ácido 5' guanílico transformante dna recombinante proteina e gene | |
| WO2001031008A3 (en) | Human and rat fgf-20 genes and gene expression products | |
| EA200001246A1 (ru) | Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот | |
| ATE291095T1 (de) | Enzymatisches verfahren zur stereoselektiven herstellung von therapeutischen amiden | |
| ATE232721T1 (de) | Verfahren zur vermehrung der produktion und zur verbesserung der qualität von sperma | |
| DE69519799D1 (de) | Verfahren zur herstellung von [s,s]-ethylendiamin-n,n'-dibernsteinsäure | |
| DE69738985D1 (de) | Raffinosesynthetase gen, verfahren zur herstellung von raffinose und transformierte pflanze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1007638 Country of ref document: EP |